|
|
| (3 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Argatroban#Adverse Reactions]] |
| {{Argatroban}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
| |
| | |
| ====6.1 Adverse Events in Patients with HIT (With or Without Thrombosis)====
| |
| | |
| The following safety information is based on all 568 patients treated with argatroban in Study 1 and Study 2. The safety profile of the patients from these studies is compared with that of 193 historical controls in which the adverse events were collected retrospectively. Adverse events are separated into hemorrhagic and non-hemorrhagic events.
| |
| | |
| Major bleeding was defined as bleeding that was overt and associated with a hemoglobin decrease ≥2 g/dL, that led to a transfusion of ≥2 units, or that was intracranial, retroperitoneal, or into a major prosthetic joint. Minor bleeding was overt bleeding that did not meet the criteria for major bleeding.
| |
| | |
| Table 4 gives an overview of the most frequently observed hemorrhagic events, presented separately by major and minor bleeding, sorted by decreasing occurrence among argatroban-treated patients with HIT (with or without thrombosis).
| |
| {|
| |
| | [[File:Argatroban_04.png|thumb|600px]]
| |
| |}
| |
| | |
| Table 5 gives an overview of the most frequently observed non-hemorrhagic events sorted by decreasing frequency of occurrence (=2%) among argatroban-treated HIT/HITTS patients.
| |
| | |
| {|
| |
| | [[File:Argatroban_05.png|thumb|600px]]
| |
| |}
| |
| | |
| ====6.2 Adverse Events in Patients with or at Risk for HIT Patients Undergoing PCI====
| |
| | |
| The following safety information is based on 91 patients initially treated with argatroban and 21 patients subsequently re-exposed to argatroban for a total of 112 PCIs with argatroban anticoagulation. Adverse events are separated into hemorrhagic (Table 6) and non-hemorrhagic (Table 7) events.
| |
| | |
| Major bleeding was defined as bleeding that was overt and associated with a hemoglobin decrease ≥5 g/dL, that led to transfusion of ≥2 units, or that was intracranial, retroperitoneal, or into a major prosthetic joint.
| |
| | |
| The rate of major bleeding events in patients treated with argatroban in the PCI trials was 1.8%.
| |
| | |
| | |
| {|
| |
| | [[File:Argatroban_06.png|thumb|600px]]
| |
| |}
| |
| | |
| Table 7 gives an overview of the most frequently observed non-hemorrhagic events (>2%), sorted by decreasing frequency of occurrence among argatroban-treated PCI patients.
| |
| | |
| | |
| {|
| |
| | [[File:Argatroban_07.png|thumb|600px]]
| |
| |}
| |
| | |
| There were 22 serious adverse events in 17 PCI patients (19.6% in 112 interventions). Table 8 lists the serious adverse events occurring in argatroban-treated-patients with or at risk for HIT undergoing PCI.
| |
| | |
| {|
| |
| | [[File:Argatroban_08.png|thumb|600px]]
| |
| |}
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c9616c0-a299-4fd5-c8ae-79e6db453595 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| ==Reference==
| |
| | |
| {{reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Hematology]]
| |
| [[Category:Drugs]]
| |